Effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy.

OBJECTIVE

To explore the effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy (DN).

METHODS

Clinical data from 153 patients with early DN, admitted to Huzhou Central Hospital from January 2020 to December 2022, was retrospectively selected. Patients were divided into two groups based on the treatment they received: patients received Irbesartan treatment alone were assigned to Irbesartan group (n=74); patients received Irbesartan combined with Atorvastatin were assigned to combined group (n=79). Levels of renal function indicators, renal fibrosis indicators, micro inflammatory status indicators, and incidence of adverse reactions were compared between the two groups before and after the treatment.

RESULTS

After the treatment, indicators of renal function, renal fibrosis and micro-inflammation in both groups significantly decreased compared to pretreatment levels (<0.05), and were significantly lower in the combined group compared to Irbesartan group (<0.05). There was no significant difference in the incidence of adverse reactions between the groups (>0.05).

CONCLUSIONS

Compared with Irbesartan alone, Atorvastatin combined with Irbesartan is more effective in the treatment of early DN. Combined treatment regimen is able to effectively reduces the micro-inflammatory state, improve renal function and fibrosis, and is not associated with the increased risk of adverse reactions.